Carbon-14 clinical trials
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses Carbon-14 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2021 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Bial R&D Investments, S.A. (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Sirtris, a GSK Company (1) · Angion Biomedica Corp (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Carbon-14 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156CompletedPhase 1Bial R&D Investments, S.A.NCT05220072Written as Carbon-14 BIA 28-6156
- Study on Mass Balance of [14C]HSK39297 in Healthy Chinese Adult Male SubjectsCompletedPhase 1Haisco Pharmaceutical Group Co., Ltd.NCT06852092Written as Carbon-14 labeled HSK39297
- A Study to Assess the Absorption, Metabolism and Excretion of [14C]-ANG-3777Status unknownPhase 1Angion Biomedica CorpNCT04931524Written as carbon-14-[14C]-ANG-3777
- A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male SubjectsCompletedPhase 1Sirtris, a GSK CompanyNCT00937872Written as Carbon-14 radio-labeled SRT2104
Codes
What other systems call Carbon-14 · ClinicalTrials.gg INT000632
- MeSH (NLM) C000615234Carbon-14One source NLM
- UNII (FDA) 7V68J5677OCARBON C-14Confirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000615234 | Carbon-14 | One source NLM |
| UNII (FDA) | 7V68J5677O | CARBON C-14 | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.